Investigating secretome injection of mesenchymal stem cells with erbium laser in the treatment of facial atrophic scars
Phase 1
Recruiting
- Conditions
- atrophic scar.Scar conditions and fibrosis of skinL90.5
- Registration Number
- IRCT20200127046282N44
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Age between 25-45
Having middle to severe atrophic scar in face region
Exclusion Criteria
Pregnancy and breastfeeding
History of cancer
Patients with active acne
People with Mental Disorders
Active infection in the face
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the therapeutic effects of Wharton's jelly mesenchymal stem cell secretome in facial atrophic scars?
How does the combination of mesenchymal stem cell secretome and erbium laser compare to monotherapy in scar tissue remodeling?
Which biomarkers are associated with improved outcomes in erbium laser-treated patients with L90.5 skin fibrosis?
What are the potential adverse events of mesenchymal stem cell secretome injections in facial dermatology?
Are there alternative cell-derived secretome therapies or laser combinations for atrophic scar treatment in phase I/II trials?